Compare Bristol-Myers Squibb Co (BMY) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Zeta Global Holdings Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.55 (market cap $116.30B), while Zeta Global Holdings Corp trades at $22.67 (market cap $5.62B). The key difference: Bristol-Myers Squibb Co is far larger — about 20.7× Zeta Global Holdings Corp's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| BMY | ZETA | |
|---|---|---|
Market Cap | $116.30B | $5.62B |
Sector | Health | Technology |
52-Week High | $62.37 | $25.24 |
52-Week Low | $42.60 | $14.04 |
Enterprise Value | $152.24B | $5.52B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ZETA trades at $21.87, up 1.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats and accelerating revenue growth, reaching $1.3B in 2025. Recent AI partnerships with Palantir and OpenAI signal strategic transformation, though negative net margins and cash flow challenges persist. Technical indicators show bullish moving averages with RSI approaching overbought territory near 70.
ZETA presents growth potential through AI platform expansion but faces profitability challenges. The 27% upside to consensus price target of $27.50 offers opportunity, while negative margins and cash flow require monitoring. Investment thesis hinges on successful AI monetization versus ongoing margin pressure from agency-led channels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
